Last reviewed · How we verify
SELARSDI (USTEKINUMAB-AEKN)
SELARSDI (generic name: USTEKINUMAB-AEKN) is a drug developed by ALVOTECH USA INC. It is currently FDA-approved for Moderate to Severe Plaque Psoriasis, Active Psoriatic Arthritis, Moderately to Severely Active Crohn’s Disease.
SELARSDI is an interleukin-12 inhibitor, classified as an antibody drug. It is also known by other names, including STELARA and STELERA.
At a glance
| Generic name | USTEKINUMAB-AEKN |
|---|---|
| Sponsor | ALVOTECH USA INC |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Moderate to Severe Plaque Psoriasis
- Active Psoriatic Arthritis
- Moderately to Severely Active Crohn’s Disease
- Moderately to Severely Active Ulcerative Colitis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Fatigue
- Back pain
- Dizziness
- Pharyngolaryngeal pain
- Injection site erythema
- Pruritus
- Myalgia
- Depression
- Cellulitis
Serious adverse events
- Serious infections
- Malignancies (excluding non-melanoma skin cancer)
- Non-melanoma skin cancer
- Posterior reversible encephalopathy syndrome (PRES)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SELARSDI CI brief — competitive landscape report
- SELARSDI updates RSS · CI watch RSS
- ALVOTECH USA INC portfolio CI
Frequently asked questions about SELARSDI
What is SELARSDI?
SELARSDI (USTEKINUMAB-AEKN) is a pharmaceutical drug developed by ALVOTECH USA INC, indicated for Moderate to Severe Plaque Psoriasis, Active Psoriatic Arthritis, Moderately to Severely Active Crohn’s Disease.
What is SELARSDI used for?
SELARSDI is indicated for Moderate to Severe Plaque Psoriasis, Active Psoriatic Arthritis, Moderately to Severely Active Crohn’s Disease, Moderately to Severely Active Ulcerative Colitis.
Who makes SELARSDI?
SELARSDI is developed and marketed by ALVOTECH USA INC (see full ALVOTECH USA INC pipeline at /company/alvotech-usa-inc).
What is the generic name of SELARSDI?
USTEKINUMAB-AEKN is the generic (nonproprietary) name of SELARSDI.
What development phase is SELARSDI in?
SELARSDI is FDA-approved (marketed).
What are the side effects of SELARSDI?
Common side effects of SELARSDI include Nasopharyngitis, Upper respiratory tract infection, Headache, Fatigue, Back pain, Dizziness. Serious adverse events: Serious infections, Malignancies (excluding non-melanoma skin cancer), Non-melanoma skin cancer, Posterior reversible encephalopathy syndrome (PRES).
Related
- Manufacturer: ALVOTECH USA INC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Moderate to Severe Plaque Psoriasis
- Indication: Drugs for Active Psoriatic Arthritis
- Indication: Drugs for Moderately to Severely Active Crohn’s Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing